Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double Blind, Placebo-controlled, Double Dummy, 4-way Cross-over, Dose Ascending Study to Assess the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single Inhaled Doses of GSK573719 (250, 500 and 1000 μg) and Tiotropium Bromide (18 μg) Via DPI in COPD Patients.
Brief Summary: GSK573719 is a high-affinity specific muscarinic receptor (mAChR) antagonist which is being developed for once daily treatment of chronic obstructive pulmonary disease (COPD). The long duration of action of GSK573719 when administered via inhalation in animal models supports the potential for use as a once-daily bronchodilator for COPD.


Options:
A: Arm Label: Umeclidinium 62.5 mcg + placebo; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium, Drug: Umeclidinium matching placebo | Arm Label: Tiotropium 18mcg + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium, Drug: Tiotropium matching placebo | Intervention Type: DRUG; Name: Umeclidinium; Assigned to Arm(s): Umeclidinium 62.5 mcg + placebo | Intervention Type: DRUG; Name: Umeclidinium matching placebo; Assigned to Arm(s): Umeclidinium 62.5 mcg + placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium 18mcg + placebo | Intervention Type: DRUG; Name: Tiotropium matching placebo; Assigned to Arm(s): Tiotropium 18mcg + placebo
B: Arm Label: FF/VI 100/25 mcg + UMEC (62.5mcg); Type: EXPERIMENTAL; Interventions: Drug: FF, Drug: VI, Drug: UMEC | Arm Label: FF/VI 100/25 mcg + UMEC (125mcg); Type: EXPERIMENTAL; Interventions: Drug: FF, Drug: VI, Drug: UMEC | Arm Label: FF/VI 100/25 mcg + Placebo; Type: EXPERIMENTAL; Interventions: Drug: FF, Drug: VI, Drug: Placebo | Intervention Type: DRUG; Name: FF; Assigned to Arm(s): FF/VI 100/25 mcg + Placebo, FF/VI 100/25 mcg + UMEC (125mcg), FF/VI 100/25 mcg + UMEC (62.5mcg) | Intervention Type: DRUG; Name: VI; Assigned to Arm(s): FF/VI 100/25 mcg + Placebo, FF/VI 100/25 mcg + UMEC (125mcg), FF/VI 100/25 mcg + UMEC (62.5mcg) | Intervention Type: DRUG; Name: UMEC; Assigned to Arm(s): FF/VI 100/25 mcg + UMEC (125mcg), FF/VI 100/25 mcg + UMEC (62.5mcg) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): FF/VI 100/25 mcg + Placebo
C: Arm Label: Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 2: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719 | Arm Label: Seq 3: UMEC 250 µg, placebo, UMEC 500 µg, UMEC 1000 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719 | Arm Label: Seq 4: UMEC 250 µg, UMEC 500 µg, placebo, UMEC 1000 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719 | Arm Label: Seq 5: Placebo, UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719 | Arm Label: Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Arm Label: Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg; Type: ACTIVE_COMPARATOR; Interventions: Drug: GSK573719, Drug: Tiotropium | Intervention Type: DRUG; Name: GSK573719; Assigned to Arm(s): Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg, Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg, Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg, Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo, Seq 2: UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, placebo, Seq 3: UMEC 250 µg, placebo, UMEC 500 µg, UMEC 1000 µg, Seq 4: UMEC 250 µg, UMEC 500 µg, placebo, UMEC 1000 µg, Seq 5: Placebo, UMEC 250 µg, UMEC 500 µg, UMEC 1000 µg, Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg, Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg, Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Seq 10: Tiotropium 18 µg, UMEC 250 µg, placebo, UMEC 500 µg, Seq 11: Placebo, UMEC 250 µg, Tiotropium 18 µg, UMEC 500 µg, Seq 12: UMEC 250 µg, placebo, UMEC 500 µg, Tiotropium 18 µg, Seq 1: UMEC 250 µg, UMEC 500 µg, Tiotropium 18 µg, placebo, Seq 6: UMEC 250 µg, placebo, Tiotropium 18 µg, UMEC 500 µg, Seq 7: Placebo, Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, Seq 8: Tiotropium 18 µg, placebo, UMEC 250 µg, UMEC 500 µg, Seq 9: Tiotropium 18 µg, UMEC 250 µg, UMEC 500 µg, placebo
D: Arm Label: Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS; Type: EXPERIMENTAL; Interventions: Drug: Umeclidinium bromide/Vilanterol, Drug: Placebo ACCUHALER/DISKUS | Arm Label: Fluticasone propionate/Salmeterol + placebo NDPI; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fluticasone propionate/Salmeterol, Drug: Placebo NDPI | Intervention Type: DRUG; Name: Umeclidinium bromide/Vilanterol; Assigned to Arm(s): Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS | Intervention Type: DRUG; Name: Placebo ACCUHALER/DISKUS; Assigned to Arm(s): Umeclidinium bromide/Vilanterol + placebo ACCUHALER/DISKUS | Intervention Type: DRUG; Name: Fluticasone propionate/Salmeterol; Assigned to Arm(s): Fluticasone propionate/Salmeterol + placebo NDPI | Intervention Type: DRUG; Name: Placebo NDPI; Assigned to Arm(s): Fluticasone propionate/Salmeterol + placebo NDPI

Answer: C